Welcome to our dedicated page for Lantheus Holdings news (Ticker: $LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lantheus Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lantheus Holdings's position in the market.
Lantheus (NASDAQ: LNTH) has announced the appointment of two new executives to accelerate its innovation efforts. Dr. Jeffrey S. Humphrey will join as Chief Medical Officer (CMO) and Dr. Jean-Claude Provost will take on the role of Chief Science Officer (CSO), both starting on May 28, 2024. Dr. Humphrey brings over 30 years of experience in clinical oncology and drug development, having worked with global pharmaceutical companies like Bayer and Pfizer. As CMO, he will oversee research and development, clinical development, and regulatory affairs. Dr. Provost, with a similar tenure of over 30 years, will focus on enhancing Lantheus’ pipeline and capabilities. Both appointees are expected to contribute significantly to Lantheus’ mission of better patient outcomes through innovative diagnostics and therapeutics.
Lantheus Holdings, Inc. reported a 23.0% increase in worldwide revenue to $370.0 million for the first quarter of 2024 compared to the same period in 2023. The company achieved a GAAP fully diluted net income per share of $1.87, a significant improvement from a net loss per share of $0.04 in the first quarter of 2023. Adjusted fully diluted net income per share reached $1.69, up from $1.47 in the previous year. Lantheus also enhanced its full-year 2024 net revenue and earnings guidance while providing guidance for the second quarter of 2024. The company's strong financial position and market-leading commercial portfolio set the stage for continued growth through investments in current business operations, business development, and M&A opportunities in diagnostics and therapeutics.